Tumor necrosis factor-alpha (TNF-α) inhibitors are a cornerstone in the management of chronic immune-mediated diseases, including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis [1], and, in selected cases, refractory sarcoidosis [2]. The gene discussed is TNF; the disease is psoriasis vulgaris.